CTRI/2023/03/051072招募中2 期
A Prospective, Multicenter, Randomized, Open Label, Active Controlled, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Dose Combination (FDC) of Doxycycline Hyclate and Metformin Hydrochloride (10%w/w + 1%w/w) Gel in the Treatment Of Adults With Periodontitis
试验速览
- 阶段
- 2 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female subjects between 18 – 65 years of age (Both inclusive), with a clinical diagnosis of Stage III or stage IV periodontitis characterized by =5 mm interdental clinical attachment loss (CAL) and pockets measured with probing depth (PD) =6 mm.
- •2. Subjects with =14 natural teeth.
- •3. Willing to provide written informed consent and comply with study instructions for its duration.
- •4. In good general health other than periodontitis according to medical history, physical examination and clinical judgment undertaken by investigator.
- •5. Non-alcoholics & Non-smokers / Ex-smokers (at least 2years of abstinence)
- •6. Able to follow written and verbal instructions, perform oral hygiene as specified in the protocol, & return to the center for specified study visits.
- •7. Negative serum pregnancy test prior to beginning therapy and agreement to use adequate birth control during the study for females of child-bearing potential.
排除标准
- •1. Known hypersensitivity to Doxycycline Hyclate or other Tetracyclines and/or Metformin/Biguanide group or any excipients or any related drug or any substance.
- •2. Compromised renal function (as indicated by serum creatinine levels > 1.5 times ULN)
- •3. Ongoing systemic cancer chemotherapy and/or radiation therapy.
- •4. Known history or presence of tobacco chewing and / or betel nut usage.
- •5. Known history or presence of clinically significant acute or chronic illness such as Diabetes Mellitus, Neutropenia (Severe and/or acquired), Inflammatory Bowel Disease (IBD), Osteoporosis, Hyperparathyroidism, Oral candidiasis, Rheumatic fever, Cancer, Connective tissue disease (such as Systemic Lupus Erythematosus (SLE), Lichen Planus, Rheumatoid Arthritis (RA), Systemic sclerosis (scleroderma) and Ankylosing Spondylitis) etc.,
- •6. Presence of clinically significant cardiovascular, Hepatic, Pulmonary, Neurologic, Renal or Psychiatric disorder, or clinically significant laboratory abnormalities as judged by investigator
- •7. A positive hepatitis screen including positive test result for hepatitis B surface antigen and/or HCV antibodies & HIV antibody (I & II).
- •8. Prior/Ongoing treatment with the following medications:
- •Mouthwash with known antibacterial properties (regularly within 1 month prior to baseline examination)
- •? Antimicrobials (6 weeks prior to baseline examination)
- •? Sulfasalazine and/or drugs causing gingival hyperplasia such as Phenytoin and other anticonvulsants (Phenobarbital, Lamotrigine, Vigabatrin, Ethosuximide, Topiramate and Primidone) or Cyclosporine or Calcium Channel Blockers (CCB) such as Nifedipine, Amlodipine, and Verapamil) (within 3 months prior to baseline examination)
- •? Systemic, topical application inside oral cavity & inhalational corticosteroids or Oral Bisphosphonates (6 months prior to baseline examination)
- •? Patients on systemic metformin therapy
- •9. Any need for systemic or local antibiotic prophylaxis prior to enrollment (e.g., for recent orthopedic implants, Patients with a prosthetic heart valve etc.,)
- •10. Ongoing pregnancy, lactation or plan of pregnancy during the proposed study period or not using an acceptable method of birth control (IUD, Norplant, Depo-Provera, Diaphragm, or Condom).
- •11. Enrolled in any other investigational medication study currently, or within the last 6 months.
- •12. Investigators opinion that subject is not suitable for the study otherwise.
- •13. Periodontitis disease specific exclusion criteria:
- •a. Accumulation of substantial sub-gingival calculus defined as 80% or greater surfaces of the dentition having dental calculus. (Process of assessing this will be explained in separate study specific dental assessment manual)
- •b. Undergone
- •? SRP (Scaling and Root Planning) therapy (less than 6 months prior to base line examination)
- •? Surgical periodontal treatment (within past 6 months or scheduled during the study) or
- •? Orthodontic therapy including removable partial denture (ongoing or scheduled during the study)
- •c. Requirement of restorative and endodontic therapy during the study period
- •d. Periodontal sites with Class III furcation
- •e. CAL is only due to local factor
研究者
相似试验
招募中
3 期
This study is to evaluate benefit of adding Molnupiravir over standard treatments in mild COVID-19 subjectsCTRI/2021/06/033938Dr Reddys Laboratories Limited
进行中（未招募）
1 期
Study comparing the action of drugs : ticagrelor, clopidogrel combined with acetylsalicylic acid in preventing ischemic strokes during transcatheter aortic valve implantation operations.Preventing cerebrovascular embolic events during the TAVI procedureMedDRA version: 19.0Level: PTClassification code 10002918Term: Aortic valve stenosisSystem Organ Class: 10007541 - Cardiac disordersEUCTR2015-005630-21-GRational and Kapodistrian University of Athens
已完成
3 期
Effect of Tofacitinib Ointment 2% w/w compared to Pimecrolimus Cream 1% w/w in Patients with Mild to Moderate Atopic Dermatitis (AD).CTRI/2022/07/044136Intas Pharmaceuticals Ltd184
招募中
2 期
Study of the effect of Siddha Treatment in addition to standard therapy in COVID-19 patientsCTRI/2020/06/025625Eminentlabs Business Solutions Pvt Ltd
进行中（未招募）
不适用
A study of the safety and efficacy of ABH001 in the treatment of patients with epidermolysis bullosa who have wounds that are not healing.Epidermolysis bullosaEUCTR2012-001815-21-PTShire Regenerative Medicine, Inc.26